TEM
Tempus AI, Inc.
NASDAQ · Healthcare · Medical - Healthcare Information Services · US
$77.84
−3.14%Sep 19, 2026, 01:46 UTC
Tempus AI CEO and Chairman Eric P. Lefkofsky sold 200,000 shares of Class A Common Stock for approximately $16.1 million on September 17, 2026, under a Rule 10b5-1 trading plan adopted on March 8, 2026.
Source:Sep 19, 2026, 01:45 UTC
Andrew Polovin, Executive Vice President and Chief Legal Officer of Tempus AI, Inc., sold 2,951 shares of the company's Class A Common Stock for $221,325 on September 17, 2026, under a Rule 10b5-1 trading plan.
Source:Sep 19, 2026, 01:45 UTC
Tempus AI Chief Accounting Officer Ryan M. Bartolucci sold 7,062 shares of Class A common stock for $529,650 on September 17, 2026, under a Rule 10b5-1 trading plan.
Source:Sep 18, 2026, 13:30 UTC
Tempus AI stock jumped to $80, up 95% from its lowest level this year, reaching its highest level since November last year with a market capitalization above $14 billion.
Source:Sep 18, 2026, 11:50 UTC
Tempus AI shares jumped 14.9% in the last trading session on above-average volume.
Source:Sep 12, 2026, 18:00 UTC
Tempus partnered with Merck on AI-driven precision medicine.
Source:Sep 11, 2026, 12:31 UTC
Tempus AI announced plans to build the largest multimodal whole-genome dataset.
Sep 9, 2026, 16:01 UTC
ARPA-H announced the first batch of awards totaling $62.7 million to develop FDA-authorized AI for heart failure treatment, with $33.7 million committed for the first year.
Source:Aug 24, 2026, 12:30 UTC
Tempus AI, Inc. received FDA 510(k) clearance for its AI-enabled software device Tempus ECG-PH, which analyzes standard 12-lead ECGs to detect signs of pulmonary hypertension.
Source:Aug 22, 2026, 07:03 UTC
Tempus AI shares rose 8.3% in mid-day trading on Friday after BTIG Research raised its price target from $70.00 to $80.00.
Source:Aug 20, 2026, 07:24 UTC
Bank of America Corp DE reduced its stake in Tempus AI, Inc. by 63.6% during the quarter, selling 725,709 shares and retaining 414,780 shares, as disclosed in its 13F filing with the SEC.
Source:Aug 13, 2026, 14:11 UTC
Tempus AI received FDA approval for its xT product, potentially enabling higher pricing and reimbursement.
Source:Aug 11, 2026, 07:00 UTC
Bios Life announced a multi-year partnership with Tempus, including commercial rights to BioNTech-InstaDeep's genomics AI.
Aug 6, 2026, 13:15 UTC
CellCarta announced a strategic collaboration with Tempus AI to add Tempus as a second commercial laboratory partner in its CDx commercialization lab network, supporting oncology-focused access within CellCarta's CDx Accelerator Model.
Source:Aug 4, 2026, 18:04 UTC
Wohl & Fruchter LLP announced an investigation into the fairness of the proposed acquisition of Personalis, Inc. by Tempus AI, Inc. for $16.25 per share.
Source:Jul 30, 2026, 20:01 UTC
Tempus AI, Inc. reported financial results for the second quarter of 2026.
Jul 22, 2026, 12:30 UTC
Tempus AI launched its OneOme pharmacogenomics testing solution nationally in the United States.
Source:Jul 20, 2026, 12:31 UTC
TEMPUS AI will acquire PERSONALIS at $16.25 per share, with the transaction expected to close between late 2026 and early 2027.
Jun 9, 2026, 10:00 UTC
Ambry Genetics announced peer-reviewed research demonstrating the potential of its ExomeReveal RNA testing to improve diagnostic clarity in exome testing.
Source:Jun 3, 2026, 12:30 UTC
Tempus AI, Yale New Haven Hospital, and Memorial Sloan Kettering Cancer Center launched a digital pathology open-source consortium.
Source:May 31, 2026, 12:30 UTC
Tempus AI, Inc. launched the next-generation of its Lens agentic AI platform for oncology drug development.
Source:May 30, 2026, 12:30 UTC
Tempus AI launched the PRECISION Challenge, a national program providing access to its foundation model, data, and funding to accelerate oncology research.
May 30, 2026, 12:00 UTC
Tempus AI, Inc. launched Tempus Preview, an application that provides rapid preliminary genomic insights within 24 hours of tissue receipt for precision oncology workflows.
Source: